During the last session, Moleculin Biotech Inc (NASDAQ:MBRX)’s traded shares were 0.61 million, with the beta value of the company hitting 2.17. At the end of the trading day, the stock’s price was $1.12, reflecting an intraday gain of 1.82% or $0.02. The 52-week high for the MBRX share is $10.35, that puts it down -824.11 from that peak though still a striking 64.29% gain since the share price plummeted to a 52-week low of $0.40. The company’s market capitalization is $14.90M, and the average trade volume was 5.71 million shares over the past three months.

Moleculin Biotech Inc (NASDAQ:MBRX) trade information

Moleculin Biotech Inc (MBRX) registered a 1.82% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.82% in intraday trading to $1.12, hitting a weekly high. The stock’s 5-day price performance is -13.18%, and it has moved by 12.93% in 30 days. Based on these gigs, the overall price performance for the year is -88.92%.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.25%. While earnings are projected to return 49.55% in 2025, the next five years will return 36.38% per annum.

MBRX Dividends

Moleculin Biotech Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Also, the Mutual Funds coming in first place with the largest holdings of Moleculin Biotech Inc (MBRX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 42.47 shares. This amounts to just over 0.32 percent of the company’s overall shares, with a $47564.0 market value. The same data shows that the other fund manager holds slightly less at 30.31, or about 0.23% of the stock, which is worth about $33951.0.